How Hybrid Freeze-Thaw Platforms Defy Cryoconcentration

daniel-tischler

Daniel Tischler

December 7, 2022

Table of contents

Show

Hybrid solution for drug freezing and thawing involve the use of both primary packagings, single-use bioprocess containers and bottles, the latter also known as rigid containers or PE containers. Biopharmaceutical manufacturers and CMOs typically require separate cold chain management solutions when the drug substance is filled into both single-use primary packagings during bioprocessing.

RoSS PFTU_Large Scale_Freeze-Thaw Platform_Hybrid

Advanced freeze/thaw logistics universally applicable

Along with the different shapes of bags and bottles come different freezing characteristics. While 2D single-use bags have a flat design and a low water column, they can freeze faster than bottles. This results in different types of methods for lowering the temperature of drug substance in each primary packaging. While plate freezers provide advanced freezing results, bottles are frozen by blast freezing. Both methods are integrated in hybrid freeze-thaw platforms.

Various studies, including surrogate tests, have been conducted, to evaluate the freezing results of single-use bags and bottles to prevent the effect of cryoconcentration. And since higher freezing rates are also preferred to avoid protein chemical and physical instabilities[1], fast and homogeneously frozen liquids limit cryoconcentration to a high degree, thus enabling highest product quality post-thaw.

Controlled plate-based freezing & thawing of single-use bags

Placing single-use bags in conventional static and blast ultra-cold freezer might be the simplest and most intuitive method for freezing active pharmaceutical ingredients (API). However, with conventional upright or chest freezers it takes several hours to days for all the liquid to reach -80°C. The ice front grows from the outside toward the center of the cryobag. And because water always tries to freeze in its most natural form, it pushes solutes and proteins in its center. This results in the frozen water being separated at the surface and the collected API being trapped in the center. This aggregation – better know as cryoconcentration – can be prevented by controlled and accelerated freezing, such as plate-based freezing.

cryoconcentration_bags

Fig.1: Cryoconcentration in single-use bags frozen in static freezer vs. plate freezer

 

The comparison of protein concentration between conventional and plate-based freezing is shown in Fig.1. In this study, two 10L single-use bags from the same manufacturer were filled with a protein surrogate solution. The mixture of salt and sugar was specified by a customer of Single Use Support to best mimic the freezing behavior of its product, a monoclonal antibody (mAb) formulation. To visualize the effect of cryoconcentration when drilling and sawing the frozen single-use bag, the color naphtol blue was added, which has no effect on the freezing behavior of the surrogate.

The single-use bag frozen in a static freezer showed a concentration rate of up to 212% in the lower center of the bags, where cryoconcentration occurs in most cases. In contrast, the single-use bag frozen in the plate-based freezer confirmed that cryoconcentration was largely prevented with a maximum concentration rate of 32% inside the bag.

Lower cryoconcentration has been shown to result in higher product quality of API after freezing [2]

Control over freezing and thawing of bottles

Due to their physical shape, bottles are not suitable for freezing on plates. However, there are ways to improve freezing and thawing processes for bottles as well. These are usually frozen in freezers by the air flow from integrated fans.

The combination of the hybrid RoSS.pFTU Large Scale and the use of CCUs (cryo control units) for bottles has enabled homogeneity after freezing surrogates in rigid containers to -80°C, as shown in Fig.2. In this study, two 4L bottles from the same manufacturer were filled with a protein surrogate solution. Again, the color naphtol blue was added to visualize the effect of cryoconcentration.

Homogeneity vs. volcano effect

During the freezing process of liquids in bottles, a “volcano cryo-concentration effect” is often observed (Fig. 2). The accumulation of proteins in the ice formation due to slow freezing results in an upward pressure bulge and a groove in the center of the bottle.

cryoconcentration_bottles

Fig 2: Cryoconcentration in bottles frozen in static freezer without CCU (cryo control unit) vs. frozen in RoSS.pFTU Large Scale Hybrid with CCU

 

As the name implies, cryo control units (CCU) are devices that are attached to single-use bags and bottles when they are frozen in static or blast freezers to control homogeneity and pressure at the last point of freeze in cryogenic applications in bottles. These vendor-agnostic CCU can be supplied for any type and size of bottle to ensure homogeneous freezing in the hybrid freeze/thaw platform RoSS.pFTU large scale (see Fig.3).

Bottle_CCU (3)

Fig. 3: Cryo control units (CCU) attached to bottles

Bottle thawing process

Plate-based platforms support cooling and heating of pharmaceuticals. So the same method used for freezing can also be applied for controlled thawing of single-use bags.

But what about thawing bottles? They are exposed to a warm air flow to heat liquids. In addition, the RoSS.pFTU Large Scale Hybrid has an integrated shaking function that supports the thawing process of drug substances in bottles. The linear motion which can be adjusted according to the product characteristics, avoids shaking-induced frothing.  

Supporting the start of a new era in bioprocess technology

Single-use bags promise to be the primary packaging which ensures the most efficient process and the highest quality in liquid and cold chain management. 

Bottles are still widely used due to their low cost of ownership and ease of process integration into manual processes. However, manufacturers and CMOs increasingly face challenges in contrast to bags: scalability and storage capacities due to the bulky shape, more difficult integration into automated workflows, and maintaining product quality during freezing process by avoiding cryoconcentration.

There is a trend towards single-use bags. However, bottles will not be replaced anytime soon. Hybrid solutions support manufacturers to embrace the handling of both, single-use bags and bottles. They offer them additional process flexibility and an efficient footprint by providing an all-in-one platform for state-of-the-art freezing and thawing of drug substance.

References

[1] Minatovicz B. et al.: Freeze-concentration of solutes during bulk freezing and its impact on protein stability. Journal of Drug Delivery Science and Technology 58 (2020) 101703, p.13

[2] Hauptmann A. et al.: Distribution of Protein Content and Number of Aggregates in Monoclonal Antibody Formulation After Large-Scale Freezing. AAPS PharmSciTech (2019) 20:72

daniel-tischler

Daniel Tischler

Director Commercial Operations

Daniel Tischler is Director Commercial Operations and Deputy of Chief Commercial Operations with experience in product line management, application engineer at Single Use Support.

Proximity to mechatronic systems and to customers were two constants for Daniel Tischler. At Single Use Support he started as a project manager. Later he provided customers technical insights as sales application engineer. Daniel was Head of Product Line Management working on new innovations for customers in the biopharmaceutical industry, before he has started as Director of Commercial Operations.

Daniel has gained 10+ years of expertise in design engineering and project management before he joined Single Use Support.

More from Daniel Tischler

Monoclonal Antibodies

The 3 Most Overlooked Costs in Monoclonal Antibody Production

In the quest for efficient monoclonal antibody manufacturing, it's imperative to shed light on costs that are frequently underestimated. These costs can stem from various sources, including process development, high prices associated with biotherapeutics, and the evolving landscape of production technologies.

daniel-tischler

Daniel Tischler

February 6, 2024

Vaccines

13 vaccine manufacturing companies you need to know

The vaccine market is shaped by numerous companies, from smaller newcomers to international concerns. In this article, we will uncover 13 vaccine manufacturing companies you ought to know.

daniel-tischler

Daniel Tischler

December 4, 2023

Read more about Freeze & Thaw

Freeze & Thaw

Interview with NIBRT: Innovating Freezing & Thawing in Bioprocessing

The collaboration between Single Use Support and the National Institute for Bioprocessing Research and Training (NIBRT) exemplifies a shared commitment to advancing scientific knowledge and driving innovation in the bioprocessing industry. 

micheal-eder

Michael Eder

August 13, 2024

Vaccines

Safe storage of biologics: Requirements & solutions

Once biologics are produced, they need to be stored for shorter or longer periods of time, with dedicated storage requirements to be met. Here, we will uncover these requirements, along with solutions to fulfill them.

Alexander Fuchs | Single Use Support

Alexander Fuchs

May 8, 2024

End-to-end Solution

Protein storage: How to increase protein stability?

Prior to be used in diagnostics or therapeutics, proteins have to be safely stored. In this article, we will assess methods to preserve their stability upon storage.

Alexander Fuchs | Single Use Support

Alexander Fuchs

April 10, 2024

End-to-end Solution

Protein stability – all you need to know

Protein stability is crucial to be maintained along the manufacturing process of protein-based products. In this article, we will discover what influences protein stability, along with methods to assess and increase it.

Khalil Essani - Single Use Support

Khalil Essani

April 9, 2024